PARP1 and neoplasm: Finally, our results further show that STAT3 activation was elevated in the immune cells exposed to PARP inhibitor-resistant tumor cells, which was contributed by an increase in IL-6 expression by Olaparib-resistant OVCAR8 cells relative to their parental counterparts.